[Survival of patients with metastatic breast cancer according to pathological types of tumors]. / Cáncer de mama metastásico: Caracterización de una cohorte según subtipos.

BACKGROUND: The prognosis of breast cancer (BC) is in part determined by the stage at diagnosis and its pathological characteristics. AIM: To evaluate the association between survival of women with metastatic breast cancer and pathological features of the tumor. PATIENTS AND METHODS: We obtained clinical and pathological data from patients diagnosed with a metastatic BC between 1999 and 2013. The expression of estrogen (ER) and progesterone (PR) receptors and human epidermal growth factor receptor 2 (HER2) was determined by immunohistochemistry. Clinicopathological subtypes were defined as: Luminal A: ER or PR positive, HER2 negative, histological grade (HG) 1 or 2; Luminal B: ER or PR positive, HER2 negative or positive or HG 3; triple negative (TN): ER, PR and HER2 negative, independent of the HG, positive HER2: ER, PR negative and HER2 positive, independent of HG. We analyzed survival based on these subtypes. RESULTS: We identified 54 patients aged 24 to 85 years, with metastatic BC at diagnosis. Seventy five percent had luminal tumors; 19.6% HER2 positive and 7.8% were TN. In 61% of evaluable tumors, HG was classified as 3. The frequency of HER2 positive and high HG tumors was greater in these patients with metastatic BC than in a non-metastatic local BC cohort. Survival was higher among patients with Luminal tumors than in women with non-Luminal cancer (56.4 and 11.4 months, respectively, p = 0.04). CONCLUSIONS: Patients with metastatic BC at diagnosis often had HER2 positive tumors and high HG. As in other studies, ER positive tumors had a better survival.

Características clínico-patológicas y sobrevida de pacientes con cáncer de mama bilateral sincrónico / Clinicopathological features and survival of patients with bilateral synchronous breast cancer

Introduction: Bilateral synchronous breast cancer (BSBC) has a variable incidence and conflicting data on prognosis. Our goal is to evaluate the characteristics and survival of patients with BSBC treated at Cancer Center of the Pontificia Universidad Católica de Chile. Patients and Methods: Descriptive study. We identified patients treated between January 1999 and May 2013. We evaluated and compared characteristics from BSBC patients with a local cohort of non-synchronous breast cancer. Results: The incidence of BSBC was 1.8 percent (n = 28). Three patients were excluded because of missing data. Therefore we analyzed 25 patients (50 tumors). Median age: 50 years (33-84). The dominant tumor's diagnosis was clinical in 47.6 percent of cases, and imaging in 90.5 percent of the contra-lateral non-dominant (p = 0.04). Average tumor size of invasive tumors was 2.5 cm for dominant tumor versus 1.7 cm for the non-dominant (p = 0.02). 81.4 percent of invasive tumors were estrogen receptor (ER) positive. Histological and subtype concordance between both tumors was 88 percent and 72 percent respectively. 54 percent of patients with BSBC were managed with total mastectomy versus 28.4 percent in the control group no BSBC (p = 0.0001). The estimated overall survival at 10 years was 76.5 percent in patients with no BSBC versus 62 percent in those with BSBC (p = 0.08). Conclusions: The BSBC is rare. Frequently they are ER positive tumors, mostly diagnosed through images and managed with less conservative surgery.

Introducción: La incidencia y pronóstico del Cáncer de mama (CM) bilateral sincrónico (CMBS), no son bien conocidos. Evaluamos las características y sobrevida de pacientes con CMBS tratadas en el Centro de Cáncer de la Pontificia Universidad Católica de Chile. Pacientes y Método: Estudio descriptivo. Identificamos pacientes con CMBS tratadas entre enero de 1999 y mayo de 2013. Evaluamos sus características y las comparamos con una cohorte local de CM no sincrónico. Resultados: La incidencia de CMBS fue de 1,8 por ciento (n = 28). Se excluyeron 3 pacientes por falta de datos. Analizamos por tanto, 25 pacientes (50 tumores). Mediana de edad: 50 años (33-84). El diagnóstico del tumor dominante fue clínico en el 47,6 por ciento de los casos, y por imágenes en 90,5 por ciento de los contra-laterales no dominantes (p = 0,04). Tamaño tumoral promedio de los tumores invasores fue de 2,5 cm en tumores dominantes vs 1,7 cm en los no dominantes (p = 0,02). Un 81,4 por ciento de los tumores invasores fueron receptor de estrógenos (RE) positivos. La concordancia histológica y de subtipo histológico entre ambos tumores fue de 88 por ciento y 72 por ciento respectivamente. Un 54 por ciento de las pacientes con CMBS fueron manejadas con mastectomía total versus un 28,4 por ciento en el grupo control de CM no BS (p = 0,0001). La sobrevida global estimada a 10 años fue de un 76,5 por ciento en pacientes con CM no BS versus 62 por ciento en aquellos con CMBS (p = 0,08). Conclusiones: El CMBS es poco frecuente. Usualmente son tumores RE positivos que reciben con menos frecuencia manejo conservador de la mama.

Cáncer de mama metastásico: Caracterización de una cohorte según subtipos / Survival of patients with metastatic breast cancer according to pathological types of tumors

Background: The prognosis of breast cancer (BC) is in part determined by the stage at diagnosis and its pathological characteristics. Aim: To evaluate the association between survival of women with metastatic breast cancer and pathological features of the tumor. Patients and Methods: We obtained clinical and pathological data from patients diagnosed with a metastatic BC between 1999 and 2013. The expression of estrogen (ER) and progesterone (PR) receptors and human epidermal growth factor receptor 2 (HER2) was determined by immunohistochemistry. Clinicopathological subtypes were defined as: Luminal A: ER or PR positive, HER2 negative, histological grade (HG) 1 or 2; Luminal B: ER or PR positive, HER2 negative or positive or HG 3; triple negative (TN): ER, PR and HER2 negative, independent of the HG, positive HER2: ER, PR negative and HER2 positive, independent of HG. We analyzed survival based on these subtypes. Results: We identified 54 patients aged 24 to 85 years, with metastatic BC at diagnosis. Seventy five percent had luminal tumors; 19.6% HER2 positive and 7.8% were TN. In 61% of evaluable tumors, HG was classified as 3. The frequency of HER2 positive and high HG tumors was greater in these patients with metastatic BC than in a non-metastatic local BC cohort. Survival was higher among patients with Luminal tumors than in women with non-Luminal cancer (56.4 and 11.4 months, respectively, p = 0.04). Conclusions: Patients with metastatic BC at diagnosis often had HER2 positive tumors and high HG. As in other studies, ER positive tumors had a better survival.